Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6763-6771

  Giafis, Nick ^a   Katsoulidis, Efstratios ^a   Sassano, Antonella ^a   Tallman, Martin S ^a   Higgins, Linda S ^b   Nebreda, Angel R ^c   Davis, Roger J ^d   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SCIOS INC   (United States)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ARSENIC TRIOXIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN BCL 2; SCIO 469; SD 282; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL MEMBRANE POTENTIAL; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE DISRUPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINE, TUMOR; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, PROMYELOCYTIC, ACUTE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

EID: 33746178172     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3699     Document Type: Article

References (50)

1. Tallman MS. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. Blood Rev 2001;15:133-42.
2. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759-67.
3. Davison K, Mann KK, Miller WH, Jr. Arsenic trioxide: mechanisms of action. Semin Hematol 2002;39:3-7.
4. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001;15:735-41.
5. O'Dwyer ME, La Rosee P, Nimmanapalli R, Bhalla KN, Druker BJ. Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Semin Hematol 2002;39:18-21.
6. Chen Z, Chen GQ, Shen ZX et al. Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 2002;39:22-6.
7. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
8. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 2000;95:1014-22.
9. Puccetti E, Culler S, Orleth A, et al. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000;60:3409-13.
10. Nimmanapalli R, Bali P, O'Bryan E, et al. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res 2003;63:7950-8.
11. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-44.
12. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667-79.
13. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002;20:55-72.
14. Verma A, Mohindru M, Deb DK, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002;277:44988-95.
15. Branche D, Tanaka N, Jaeschke A, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003;17:1969-78.
16. Adams RH, Porras A, Alonso G, et al. Essential role of p38oi MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 2000;6:109-16.
17. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000;288:870-4.
18. Hideshima T, Podar K, Chauhan D, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004;23:8766-76.
19. Lim MY, Wang H, Kapoun AM, et al. p38 inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. J Mol Cell Cardiol 2004;37:1111-4.
20. Uddin S, Majchrzak B, Woodson J, et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem 1999;274:30127-31.
21. Li Y, Sassano A, Majchrzak B, et al. Role of p38a Map kinase in type I Interferon signaling. J Biol Chem 2004;279:970-9.
22. Alsayed Y, Uddin S, Mahmud N, et al. Activation of Racl and the p38 mitogen-activated protein kinase pathway in response to all-ira/zs-retinoic acid. J Biol Chem 2001;276:4012-9.
23. Verma A, Deb DK, Sassano A, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol 2002;168:5984-8.
24. Han J, Lee J-D, Jiang Y, Zhuangjie L, Feng L, Ulevitch RJ. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). Mol Cell Biol 1996;271:2886-91.
25. Moriguchi T, Kuriyanagi N, Yamaguchi K, et al. A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J Biol Chem 1996;71:13765-9.
26. Nikas SN, Drosos AA. SCIO-469 Scios, Inc. Curr Opin Investig Drugs 2004;5:1205-12.
27. Davison K, Mann KK, Waxman S, Miller WH, Jr. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004;103:3496-502.
28. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
29. 3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996;88:1052-61.
30. Konig A, Wrazel L, Warrell RP, Jr., et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997;90:562-70.
31. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol 1998;102:1055-60.
32. Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000;60:3065-71.
33. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102-11.
34. Wang ZG, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 1998;92:1497-504.
35. Mahieux R, Pise-Masison C, Gessain A, et al. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001;98:3762-9.
36. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805-13.
37. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003;5:931-40.
38. Denis FM, Benecke A, Gi Gioia Y, Touw IP, Cayre YE, Lutz PG. PRAM-1 potentiates arsenic trioxide-induced JNK activation. J Biol Chem 2005;280:9043-8.
39. Lunghi P, Tabilio A, Lo-Coco F, Pelicci P, Bonati A. Arsenic trioxide and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia 2005;19:234-44.
40. Nebreda AR, Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000;25:257-60.
41. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
42. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997;275:90-4.
43. Krumer JL, Rao PK, Heidenreich KA. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1997;272:20490-4.
44. Sarkar D, Su ZZ, Lebedeva IV, et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci U S A 2002;99:10054-9.
45. Pugazhenthi S, Miller E, Sable C, et al. Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem 1999;274:27529-35.
46. Juretic N, Santibanez JF, Hurtado C, Martinez J. ERK 1,2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line. J Cell Biochem 2001;83:92-8.
47. Wang Y, Huang S, Sah W, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998;273:2161-8.
48. Cheung PC, Campbell DG, Nebreda AR, Cohen P. Feedback control of the protein kinase TAKl by SAPK2a/p38α. EMBO J 2003;22:5793-805.
49. Zhang Y, Shen WL. Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide. Cell Biol Int 2003;27:953-8.
50. Zheng Y, Shi Y, Tian C, et al. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene 2004;23:1239-47.